Open Collections

UBC Faculty Research and Publications

Benign Prostatic Hypertrophy : An update on drug therapy Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 58 provides an update on drug therapy for benign prostatic hypertrophy (BPH). Conclusions: Alpha blockers improve symptoms on average by 2-3 points more than placebo (35 point AUAscale), a difference patients perceive as ‘slight benefit’. Alpha blockers do not reduce complications, but increase dizziness, postural hypotension and asthenia (ARI 3-8%, NNH 13-33). 5-a-reductase inhibitors reduce acute urinary retention (ARR 2%, NNT 50), and BPH surgery (ARR 2-3%, NNT 33-50), but impair sexual function (ARI 3%, NNH 33). There is insufficient evidence that combining the two drug classes provides additional benefit. Most BPH trials do not report total serious adverse events and mortality. This prevents an assessment of the overall clinical impact of drug treatment.

Item Metadata

Title
Benign Prostatic Hypertrophy : An update on drug therapy
Alternate Title
Therapeutics Letter 58
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2006-03
Description
Therapeutics Letter 58 provides an update on drug therapy for benign prostatic hypertrophy (BPH). Conclusions: Alpha blockers improve symptoms on average by 2-3 points more than placebo (35 point AUAscale), a difference patients perceive as ‘slight benefit’. Alpha blockers do not reduce complications, but increase dizziness, postural hypotension and asthenia (ARI 3-8%, NNH 13-33). 5-a-reductase inhibitors reduce acute urinary retention (ARR 2%, NNT 50), and BPH surgery (ARR 2-3%, NNT 33-50), but impair sexual function (ARI 3%, NNH 33). There is insufficient evidence that combining the two drug classes provides additional benefit. Most BPH trials do not report total serious adverse events and mortality. This prevents an assessment of the overall clinical impact of drug treatment.
Subject
Adrenergic alpha-Antagonists; Drug-Related Side Effects and Adverse Reactions; Prostatic Hyperplasia
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433637
URI
http://hdl.handle.net/2429/85047
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International